STOCK TITAN
  1. Home
  2. Sec-filings
  3. NTRA
  4. [Form 4] Natera, Inc. Insider Trading Activity

Natera officer sells 18,160 shares of stock

Natera’s President, Clinical Diagnostics disclosed pre-arranged sales of 18,160 shares, including a sizable sale to cover RSU-related tax obligations.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Natera, Inc. (NTRA) reported that Solomon Moshkevich, its President, Clinical Diagnostics, sold a total of 18,160 shares of common stock in early September 2026. On September 1, 2026, he sold 3,000 shares in multiple transactions pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024, at weighted average prices between $319.29 and $322.11 per share. On September 2, 2026, he sold 15,160 shares at $326.89 per share to satisfy tax withholding and remittance obligations related to vesting RSUs, under written instructions intended to meet the affirmative defense conditions of Rule 10b5-1(c).

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Moshkevich Solomon
Role PRESIDENT, CLINICALDIAGNOSTICS
Sold 18,160 shs ($5.92M)
Type Security Shares Price Value
Sale Common Stock F5 15,160 $326.894 $4.96M
Sale Common Stock F1, F2 1,000 $319.7582 $320K
Sale Common Stock F1, F3 1,400 $320.9225 $449K
Sale Common Stock F1, F4 600 $321.9067 $193K
Holdings After Transaction: Common Stock — 110,859 shares (Direct)
Footnotes (5)
  1. F1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
  2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023.
Total shares sold 18,160 shares Aggregate of all reported sales on September 1–2, 2026
Shares sold on September 1, 2026 3,000 shares Sales under a Rule 10b5-1 trading plan adopted November 26, 2024
Shares sold on September 2, 2026 15,160 shares Sale to satisfy RSU-related tax withholding and remittance obligations
Sale price on September 2, 2026 $326.8940 per share 15,160-share sale for tax withholding and remittance obligations
Weighted average price block 1 $319.7582 per share 1,000 shares sold September 1, 2026 in trades from $319.2850 to $320.26
Weighted average price block 2 $320.9225 per share 1,400 shares sold September 1, 2026 in trades from $320.36 to $321.17
Weighted average price block 3 $321.9067 per share 600 shares sold September 1, 2026 in trades from $321.49 to $322.11
Rule 10b5-1 plan adoption date November 26, 2024 Date the reporting person adopted the trading plan governing September 1, 2026 sales
Rule 10b5-1 trading plan regulatory
"The sale of shares was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The reported price in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding and remittance obligations financial
"effected in order to satisfy tax withholding and remittance obligations in connection"
RSUs financial
"tax withholding and remittance obligations in connection with the vesting of RSUs"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
affirmative defense conditions of Rule 10b5-1(c) regulatory
"intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)"

FAQ

Who from Natera (NTRA) reported transactions in this Form 4?
The filing reports transactions by Solomon Moshkevich, who serves as President, Clinical Diagnostics at Natera, Inc. He is identified as an officer of the company and not as a director or ten percent owner.

How many NTRA shares did Solomon Moshkevich sell and on what dates?
He reported selling a total of 18,160 shares of Natera common stock: 3,000 shares on September 1, 2026, and 15,160 shares on September 2, 2026.

At what prices were the NTRA shares sold in this Form 4?
On September 1, 2026, 1,000 shares were sold at a weighted average price of $319.7582, 1,400 at $320.9225, and 600 at $321.9067. On September 2, 2026, 15,160 shares were sold at $326.8940 per share.

Were the NTRA share sales made under a Rule 10b5-1 trading plan?
Yes. The September 1, 2026 sales of Natera shares were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024, and the Form 4 affirms Rule 10b5-1 status at the document level.

Why did Solomon Moshkevich sell 15,160 NTRA shares on September 2, 2026?
The Form 4 states that the 15,160-share sale on September 2, 2026 was made to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs, under written instructions intended to satisfy Rule 10b5-1(c) affirmative defense conditions.

How were the NTRA share prices determined for the September 1, 2026 sales?
For the September 1, 2026 Natera share sales, each reported price is a weighted average price. The shares were sold in multiple transactions within ranges of $319.2850–$320.26, $320.36–$321.17, and $321.49–$322.11 per share, with detailed breakdowns available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Moshkevich Solomon
(Last)(First)(Middle)
C/O NATERA, INC.
13011 MCCALLEN PASS BUILDING A SUITE 100
(Street)
AUSTIN TEXAS 78753
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Natera, Inc. [ NTRA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
PRESIDENT, CLINICALDIAGNOSTICS
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock09/01/2026S1,000(1)D$319.7582(2)128,019D
Common Stock09/01/2026S1,400(1)D$320.9225(3)126,619D
Common Stock09/01/2026S600(1)D$321.9067(4)126,019D
Common Stock09/02/2026S15,160(5)D$326.894110,859D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023.
/s/ Tami Chen, Attorney-in-Fact09/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR